Pentagon Awards Cardinal Health $1.5 Billion Contract
Cardinal Health has been awarded a $1.5 billion government contract to supply medical and surgical products under the Defense Department's Prime Vendor program.
Stocks · News reference
Mizuho Maintains Outperform on Cardinal Health, Raises Price Target to $280
Mizuho analyst Steven Valiquette maintains Cardinal Health (NYSE:CAH) with a Outperform and raises the price target from $250 to $280.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x). Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.
UBS Maintains Buy on Cardinal Health, Raises Price Target to $295
UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $280 to $295.